SCHEMBL2289385

SCHEMBL2289385

Cc1cccc(C)c1Nc1c(-c2c(C)cc(OCCN(C)C)cc2OCC(N)=O)nc2ccc(F)cn12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.39
CDK2 P24941 1/20 0.39
IGF1R P08069 5/20 0.35
GAA P10253 5/20 0.35
MAPT P10636 3/20 0.35
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
TP53 P04637 1/20 0.35
INSR P06213 1/20 0.34
GABRA1 P14867 2/20 0.33
GABRB2 P47870 2/20 0.33
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
LCK P06239 1/20 0.32
SRC P12931 1/20 0.32
KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2288570 0.94 CDK2 (0.42) TRPA1CDK2IGF1RGAAMAPT
SCHEMBL2290253 0.92 TRPA1 (0.41) TRPA1GAAMAPTTP53MAPK1
SCHEMBL2291220 0.92 TRPA1 (0.42) TRPA1GAAMAPTTP53MAPK1
SCHEMBL2287514 0.92 TRPA1 (0.41) TRPA1GAAMAPTTP53MAPK1
SCHEMBL2290061 0.91 TRPA1 (0.42) TRPA1GAAMAPTTP53MAPK1
SCHEMBL2287331 0.90 TRPA1 (0.40) TRPA1GAAMAPTTP53MAPK1
SCHEMBL2289183 0.89 TRPA1 (0.42) TRPA1GAAMAPTTP53MAPK1
SCHEMBL2289166 0.89 MAPT (0.44) IGF1RGAAMAPTEGFRERBB2
SCHEMBL12083142 0.87 TRPA1 (0.37) TRPA1GAAMAPTTP53GABRA1
SCHEMBL2290031 0.87 TRPA1 (0.42) TRPA1GAAMAPTTP53GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 TRPA1 1229/4885CDK2 1200/4885IGF1R 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.